USPTO Examiner ROBINSON CARY MICHAEL - Art Unit 2923

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
29998876DISPLAY SCREEN WITH GRAPHICAL USER INTERFACEApril 2025May 2025Allow100NoNo
29990436Computer screen with graphical user interfaceFebruary 2025July 2025Allow500NoNo
29989360DISPLAY SCREEN OR PORTION THEREOF WITH GRAPHICAL USER INTERFACEFebruary 2025October 2025Allow900NoNo
29989368DISPLAY SCREEN WITH ANIMATED GRAPHICAL USER INTERFACEFebruary 2025November 2025Allow900NoNo
29987981DISPLAY SCREEN WITH GRAPHICAL USER INTERFACEJanuary 2025August 2025Allow610NoNo
29980489DISPLAY SCREEN OR PORTION THEREOF WITH TRANSITIONAL GRAPHICAL USER INTERFACE OF X-RAY ANALYSIS APPARATUSDecember 2024September 2025Allow900NoNo
29979883DISPLAY SCREEN OR PORTION THEREOF WITH GRAPHICAL USER INTERFACEDecember 2024October 2025Allow900NoNo
29979899DISPLAY SCREEN OR PORTION THEREOF WITH GRAPHICAL USER INTERFACEDecember 2024October 2025Allow900NoNo
29979885DISPLAY SCREEN OR PORTION THEREOF WITH GRAPHICAL USER INTERFACEDecember 2024October 2025Allow900NoNo
29979887DISPLAY SCREEN OR PORTION THEREOF WITH GRAPHICAL USER INTERFACEDecember 2024October 2025Allow900NoNo
29979357DISPLAY SCREEN OR PORTION THEREOF WITH GRAPHICAL USER INTERFACEDecember 2024August 2025Allow800NoNo
29979092DISPLAY SCREEN WITH GRAPHICAL USER INTERFACE FOR BACTERIA MEASURING INSTRUMENTDecember 2024September 2025Allow900NoNo
29979116DISPLAY SCREEN WITH GRAPHICAL USER INTERFACE FOR BACTERIA MEASURING INSTRUMENTDecember 2024September 2025Allow900NoNo
29979085DISPLAY SCREEN WITH GRAPHICAL USER INTERFACE FOR BACTERIA MEASURING INSTRUMENTDecember 2024September 2025Allow900NoNo
29979095DISPLAY SCREEN WITH GRAPHICAL USER INTERFACE FOR BACTERIA MEASURING INSTRUMENTDecember 2024September 2025Allow900NoNo
29979082DISPLAY SCREEN WITH ANIMATED GRAPHICAL USER INTERFACE FOR BACTERIA MEASURING INSTRUMENTDecember 2024September 2025Allow900NoNo
29979109DISPLAY SCREEN WITH GRAPHICAL USER INTERFACE FOR BACTERIA MEASURING INSTRUMENTDecember 2024September 2025Allow900NoNo
29979088DISPLAY SCREEN WITH ANIMATED GRAPHICAL USER INTERFACE FOR BACTERIA MEASURING INSTRUMENTDecember 2024September 2025Allow900NoNo
29978260Display Screen or Portion Thereof with Animated Graphical User InterfaceDecember 2024August 2025Allow900NoNo
29978280Display Screen or Portion Thereof with Graphical User InterfaceDecember 2024August 2025Allow900NoNo
29978282Display Screen or Portion Thereof with Animated Graphical User InterfaceDecember 2024August 2025Allow900NoNo
29977852DISPLAY SCREEN OR PORTION THEREOF WITH A TRANSITIONAL GRAPHICAL USER INTERFACEDecember 2024June 2025Allow600NoNo
29977173Display Screen with Graphical User InterfaceDecember 2024August 2025Allow900NoNo
29974324DISPLAY SCREEN OR PORTION THEREOF WITH GAME BOARD GUINovember 2024September 2025Allow1000NoNo
29972941DISPLAY PANEL OR PORTION THEREOF WITH GRAPHICAL USER INTERFACENovember 2024September 2025Allow1000NoNo
29972028Display Screen with Animated Graphical User Interface of a Gaming MachineNovember 2024August 2025Allow1000NoNo
29967916Type FontOctober 2024August 2025Allow1000NoNo
29961722DISPLAY SCREEN OR PORTION THEREOF WITH GRAPHICAL USER INTERFACESeptember 2024June 2025Allow900NoNo
35522545TypefaceAugust 2024May 2025Allow800NoNo
29957551DISPLAY SCREEN OR PORTION THEREOF WITH GRAPHICAL USER INTERFACEAugust 2024June 2025Allow1000NoNo
29954754Display Screen or Portion Thereof with Transitional Graphical User InterfaceJuly 2024June 2025Allow1000NoNo
29951090TYPEFACEJuly 2024August 2025Allow1300NoNo
35521952Typographic typefaceJune 2024April 2025Allow1000NoNo
29946563DISPLAY SCREEN OR PORTION THEREOF WITH A GRAPHICAL USER INTERFACEJune 2024June 2025Allow1200NoNo
29946071TYPEFACEJune 2024August 2025Allow1400NoNo
29943400DISPLAY SCREEN OR PORTION THEREOF WITH A TRANSITIONAL GRAPHICAL USER INTERFACEMay 2024July 2025Allow1400NoNo
29940433TYPEFACEMay 2024August 2025Allow1600NoNo
29939376DISPLAY SCREEN WITH GRAPHICAL USER INTERFACEApril 2024June 2024Allow210YesNo
29939373DISPLAY SCREEN WITH GRAPHICAL USER INTERFACEApril 2024June 2024Allow210YesNo
29938944DISPLAY SCREEN OR PORTION THEREOF WITH GRAPHICAL USER INTERFACEApril 2024January 2025Allow900NoNo
29935942TYPE FONTApril 2024August 2025Allow1600NoNo
29935941TYPE FONTApril 2024August 2025Allow1600NoNo
29935752Typeface or Type FontApril 2024May 2025Allow1300NoNo
29934483TypefaceMarch 2024August 2025Allow1700NoNo
29933834DISPLAY DEVICE WITH GRAPHICAL USER INTERFACEMarch 2024June 2024Allow300NoNo
29933767TYPE FONTMarch 2024August 2025Allow1700NoNo
35522415TypefaceMarch 2024April 2025Allow1400NoNo
29930639TYPE FONTMarch 2024August 2025Allow1700NoNo
35524166Display screen or portion thereof with animated graphical user interfaceFebruary 2024October 2025Allow2000NoNo
29927944DISPLAY SCREEN OR PORTION THEREOF WITH GRAPHICAL USER INTERFACEFebruary 2024July 2025Allow1700NoNo
29927727TYPEFACE OR TYPE FONTFebruary 2024October 2025Allow2000NoNo
29927725TYPEFACE OR TYPE FONTFebruary 2024October 2025Allow2000NoNo
35520089Computer screen with transitional graphical user interfaceFebruary 2024January 2025Allow1101NoNo
29925518TYPEFACEJanuary 2024April 2025Allow1500NoNo
29921051DISPLAY SCREEN OR PORTION THEREOF WITH GRAPHICAL USER INTERFACEDecember 2023August 2025Allow2000NoNo
29920403TYPE FONTDecember 2023May 2025Allow1700NoNo
29916253TYPE FONTNovember 2023May 2025Allow1800NoNo
35519606Display Screen with Graphical User InterfaceOctober 2023December 2024Allow1401NoNo
35519607DISPLAY SCREEN WITH TRANSITIONAL GRAPHICAL USER INTERFACEOctober 2023December 2024Allow1401NoNo
29915184TYPE FONTOctober 2023May 2025Allow1900NoNo
29914809DISPLAY SCREEN OR PORTION THEREOF WITH ANIMATED GRAPHICAL USER INTERFACEOctober 2023July 2025Allow2100NoNo
29913769TYPE FONTOctober 2023May 2025Allow1900NoNo
29904543DISPLAY SCREEN OR PORTION THEREOF WITH GRAPHICAL USER INTERFACEOctober 2023June 2025Allow2000NoNo
35522400Printing TypeSeptember 2023April 2025Allow700NoNo
29911769DISPLAY WITH ICON FOR ORAL-CARE APPLIANCESeptember 2023November 2023Allow200NoNo
29911781DISPLAY WITH ICON FOR ORAL-CARE APPLIANCESeptember 2023July 2025Allow2200NoNo
29911774DISPLAY WITH ICON FOR ORAL-CARE APPLIANCESeptember 2023July 2025Allow2200NoNo
29911763DISPLAY WITH ICON FOR ORAL-CARE APPLIANCESeptember 2023March 2024Allow600NoNo
29911765DISPLAY WITH ICON FOR ORAL-CARE APPLIANCESeptember 2023July 2025Allow2200NoNo
29911777DISPLAY WITH ICON FOR ORAL-CARE APPLIANCESeptember 2023April 2024Allow700NoNo
29911768DISPLAY WITH ICON FOR ORAL-CARE APPLIANCESeptember 2023March 2024Allow600NoNo
29911770DISPLAY WITH ICON FOR ORAL-CARE APPLIANCESeptember 2023July 2025Allow2200NoNo
29899550DISPLAY PANEL WITH GRAPHICAL USER INTERFACEAugust 2023April 2025Allow2000NoNo
29909532DISPLAY SCREEN OR PORTION THEREOF WITH GRAPHICAL USER INTERFACEAugust 2023April 2024Allow800NoNo
29909057DISPLAY SCREEN OR PORTION THEREOF WITH TRANSITIONAL GRAPHICAL USER INTERFACEJuly 2023October 2023Allow200NoNo
29880607DISPLAY SCREEN WITH ANIMATED GRAPHICAL USER INTERFACEJuly 2023April 2025Allow2000NoNo
29896415TYPEFACEJuly 2023April 2025Allow2200NoNo
29896424TYPEFACEJuly 2023April 2025Allow2200NoNo
29894964DISPLAY SCREEN OR PORTION THEREOF WITH ANIMATED GRAPHICAL USER INTERFACEJune 2023June 2025Allow2400NoNo
29877986TYPE FONTJune 2023April 2025Allow2200NoNo
29877608TYPEFACEJune 2023April 2025Allow2200NoNo
29893815Display Screen or Portion Thereof With Graphical User InterfaceJune 2023July 2023Allow100NoNo
29893822Display Screen or Portion Thereof With Graphical User InterfaceJune 2023September 2023Allow400NoNo
29893274TYPE FONT FOR THE BLINDMay 2023May 2025Allow2300NoNo
29891260Display Screen with Transitional Graphical User InterfaceMay 2023July 2023Allow300NoNo
29891080Display Screen with Animated Graphical User InterfaceMay 2023July 2025Allow2700NoNo
29890242DISPLAY SCREEN OR PORTION THEREOF WITH GRAPHICAL USER INTERFACEApril 2023July 2023Allow200NoNo
29890147DISPLAY SCREEN OR PORTION THEREOF WITH GRAPHICAL USER INTERFACEApril 2023October 2023Allow600NoNo
29889715TYPE FONTApril 2023April 2025Allow2400NoNo
29889716TYPE FONTApril 2023April 2025Allow2400NoNo
29889446TYPE FONTApril 2023April 2025Allow2400NoNo
29888127DISPLAY SCREEN OR PORTION THEREOF WITH ICONMarch 2023October 2023Allow600NoNo
29873104DISPLAY SCREEN OR PORTION THEREOF WITH ANIMATED GRAPHICAL USER INTERFACEMarch 2023July 2023Allow400NoNo
29873106DISPLAY SCREEN OR PORTION THEREOF WITH ANIMATED GRAPHICAL USER INTERFACEMarch 2023June 2025Allow2700NoNo
29873107DISPLAY SCREEN OR PORTION THEREOF WITH ANIMATED GRAPHICAL USER INTERFACEMarch 2023July 2023Allow400NoNo
29873102DISPLAY SCREEN OR PORTION THEREOF WITH ANIMATED GRAPHICAL USER INTERFACEMarch 2023January 2024Allow900NoNo
29887889CELL COUNTER DISPLAY SCREEN WITH GRAPHICAL USER INTERFACEMarch 2023July 2023Allow400NoNo
29872854Display Screen or Portion Thereof with Transitional Graphical User InterfaceMarch 2023May 2025Allow2600NoNo
29887179Display Screen or Portion Thereof With Graphical User InterfaceMarch 2023May 2023Allow200NoNo
29886838Display Screen or Portion Thereof With Graphical User InterfaceMarch 2023April 2023Allow100NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner ROBINSON, CARY MICHAEL.

Strategic Value of Filing an Appeal

Total Appeal Filings
1
Allowed After Appeal Filing
1
(100.0%)
Not Allowed After Appeal Filing
0
(0.0%)
Filing Benefit Percentile
98.6%
Higher than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 100.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the top 25% across the USPTO, indicating that filing appeals is particularly effective here. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.

Strategic Recommendations

Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.

Examiner ROBINSON, CARY MICHAEL - Prosecution Strategy Guide

Executive Summary

Examiner ROBINSON, CARY MICHAEL works in Art Unit 2923 and has examined 1,266 patent applications in our dataset. With an allowance rate of 97.9%, this examiner allows applications at a higher rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 15 months.

Allowance Patterns

Examiner ROBINSON, CARY MICHAEL's allowance rate of 97.9% places them in the 90% percentile among all USPTO examiners. This examiner is more likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by ROBINSON, CARY MICHAEL receive 0.31 office actions before reaching final disposition. This places the examiner in the 1% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by ROBINSON, CARY MICHAEL is 15 months. This places the examiner in the 99% percentile for prosecution speed. Applications move through prosecution relatively quickly with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a -1.9% benefit to allowance rate for applications examined by ROBINSON, CARY MICHAEL. This interview benefit is in the 9% percentile among all examiners. Note: Interviews show limited statistical benefit with this examiner compared to others, though they may still be valuable for clarifying issues.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 100.0% of applications are subsequently allowed. This success rate is in the 100% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 70.0% of cases where such amendments are filed. This entry rate is in the 92% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 200.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 97% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 96% percentile among all examiners. Of these withdrawals, 100.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.

Petition Practice

When applicants file petitions regarding this examiner's actions, 38.7% are granted (fully or in part). This grant rate is in the 28% percentile among all examiners. Strategic Note: Petitions show below-average success regarding this examiner's actions. Ensure you have a strong procedural basis before filing.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 30% percentile). This examiner makes examiner's amendments less often than average. You may need to make most claim amendments yourself.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 21.8% of allowed cases (in the 94% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Consider after-final amendments: This examiner frequently enters after-final amendments. If you can clearly overcome rejections with claim amendments, file an after-final amendment before resorting to an RCE.
  • RCEs are effective: This examiner has a high allowance rate after RCE compared to others. If you receive a final rejection and have substantive amendments or arguments, an RCE is likely to be successful.
  • Request pre-appeal conferences: PACs are highly effective with this examiner. Before filing a full appeal brief, request a PAC to potentially resolve issues without full PTAB review.
  • Appeal filing as negotiation tool: This examiner frequently reconsiders rejections during the appeal process. Filing a Notice of Appeal may prompt favorable reconsideration during the mandatory appeal conference.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.